3SBio (HKSE:01530) Change In Working Capital : HK$-177 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is 3SBio Change In Working Capital?

3SBio's change in working capital for the quarter that ended in Dec. 2023 was HK$-75 Mil.

3SBio's change in working capital for the fiscal year that ended in Dec. 2023 was HK$-177 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

3SBio Change In Working Capital Historical Data

The historical data trend for 3SBio's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Change In Working Capital Chart

3SBio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

383.32

-357.83

-407.05

34.24

-177.23

3SBio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-198.07	52.98	-16.23	-102.31	-74.93

3SBio Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-177 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

3SBio Change In Working Capital Related Terms

Thank you for viewing the detailed overview of 3SBio's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (HKSE:01530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Lou Jing	2305 Beneficiary of a trust
Jpmorgan Chase & Co.	2502 Approved lending agent
Hsbc Holdings Plc	2302 Custodian
Citic Securities Company Limited	2201 Interest of corporation controlled by you
Citron Pe Associates, L.p.	2201 Interest of corporation controlled by you
Citron Pe Funds Limited	2201 Interest of corporation controlled by you
Citron Pe Holdings Limited	2201 Interest of corporation controlled by you
Cpechina Fund, L.p.	2201 Interest of corporation controlled by you
Cs Sunshine Investment Limited	2101 Beneficial owner
Tmf (cayman) Ltd.	2301 Trustee
Xing Lily
Century Sunshine Limited
Decade Sunshine Limited
Lambda International Limited

3SBio (HKSE:01530) Headlines

No Headlines